Intensity Therapeutics Inc. Company Profile
NASDAQ: INTSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Intensity Therapeutics at a glance
Intensity Therapeutics Inc. (NASDAQ: INTS) is a Biotechnology company in the Healthcare sector headquartered in Shelton, CT. Intensity Therapeutics is led by Mr. Lewis H. Bender M.A., M.B.A., M.S. and employs about 5 people. The company's shares have traded publicly since 2023.
At a market capitalization of $12.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001567264, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Intensity Therapeutics do?
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Business description based on the company's public filings.
Company information
- Legal name
- Intensity Therapeutics Inc.
- Ticker
- NASDAQ: INTS
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Lewis H. Bender M.A., M.B.A., M.S.
- Employees
- 5
- Headquarters
- 1 Enterprise Drive, Shelton, CT, United States
- Phone
- 203 221 7381
- Website
- intensitytherapeutics.com
- IPO year
- 2023
- Market cap
- $12.01M
- SEC CIK
- 0001567264
Companies similar to Intensity Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PASGPassage Bio Inc. | 3.78 | -1.95% | $12.16M | vs INTS |
| LTRNLantern Pharma Inc. | 0.83 | -8.79% | $12.40M | vs INTS |
| PLURPluri Inc. | 1.00 | -3.85% | $12.61M | vs INTS |
| PHIOPhio Pharmaceuticals Corp. | 0.9731 | -2.69% | $11.30M | vs INTS |
| GDTCCytoMed Therapeutics Limited | 0.9449 | -3.56% | $11.28M | vs INTS |
| KPRXKiora Pharmaceuticals Inc. | 2.53 | 0.00% | $11.19M | vs INTS |
| BIVIBioVie Inc. Class A | 1.28 | -8.57% | $11.11M | vs INTS |
| LSTALisata Therapeutics Inc. | 1.20 | +2.56% | $12.96M | vs INTS |